All In Biotech

Drug Trial Radar · NCT07348484

Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors

Diagnostic and Monitoring System for Chronic Kidney Disease Based on Urinary Biomarkers and Preventive Treatment With the SGLT2 Inhibitor Empagliflozin

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

Apr 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Instituto de Investigación Biomédica de SalamancaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 16, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression. No investigational product is assigned, and medical practice or prescription patterns are not altered.

Conditions

  • Chronic Kidney Disease

Interventions

  • EmpagliflozinDrug

    Oral empagliflozin (10-25 mg daily) for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in urinary biomarker panel expression (proteomic fingerprint)Time frame: Baseline, 6 months, 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario de Salamanca

    Salamanca, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.